ProCE Banner Activity

Ocular Toxicity Associated With Antibody–Drug Conjugates: A Summary Resource

PDF
Download this summary resource for a quick guide on identifying and managing ocular toxicities associated with FDA-approved antibody-drug conjugates for patients with cancer.

Released: January 31, 2022

Begin Activity

Share

Faculty

Asim V. Farooq

Asim V. Farooq, MD

Associate Professor of Ophthalmology
Vice Chair of Academic Affairs
Director of Medical Student Education
Department of Ophthalmology and Visual Science
University of Chicago Medical Center
Chicago, Illinois

Joann Kang

Joann Kang, MD

Associate Professor of Ophthalmology
Montefiore Medical Center/Albert Einstein College of Medicine
Director, Cornea and Refractive Surgery
Montefiore Medical Center
Bronx, New York

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by an educational grant from

GlaxoSmithKline

Faculty Disclosure

Primary Author

Asim V. Farooq, MD

Associate Professor of Ophthalmology
Vice Chair of Academic Affairs
Director of Medical Student Education
Department of Ophthalmology and Visual Science
University of Chicago Medical Center
Chicago, Illinois

Asim V. Farooq, MD, has disclosed that he has received consulting fees from Five Prime Therapeutics/Amgen and GlaxoSmithKline.

Joann Kang, MD

Associate Professor of Ophthalmology
Montefiore Medical Center/Albert Einstein College of Medicine
Director, Cornea and Refractive Surgery
Montefiore Medical Center
Bronx, New York

Joann Kang, MD, has no relevant conflicts of interest to report.